If you enjoy this content, please share it with a colleague
RELATED CONTENT
News
Angiotech Pharmaceuticals Inc. announced that it entered into a definitive agreement to sell certain of its subsidiaries, comprising Angiotech's interventional products business, to Argon Medical Devices Inc., a portfolio company of RoundTable Healthcare Partners, for $362.5 million in cash consideration. Angiotech expects the transaction will close prior to the end of April 2013.
News
October 12, 2007 - Angiotech Pharmaceuticals Inc. said Oct. 11 it received CE Mark approval to begin marketing the Quill ...